Selonabant

Selonabant
Clinical data
Other namesANEB-001; ANEB001; V-24343; V24343
Drug classCannabinoid receptor antagonist; Cannabinoid CB1 receptor antagonist; Cannabinoid antidote
Identifiers
  • N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H24ClF3N2O2
Molar mass440.89 g·mol−1
3D model (JSmol)
  • CC(C)(C)NC(=O)N1CC(C1)O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=C3C(F)(F)F
  • InChI=1S/C22H24ClF3N2O2/c1-21(2,3)27-20(29)28-12-16(13-28)30-19(14-8-10-15(23)11-9-14)17-6-4-5-7-18(17)22(24,25)26/h4-11,16,19H,12-13H2,1-3H3,(H,27,29)/t19-/m1/s1
  • Key:BNLYOVHLLDBOFZ-LJQANCHMSA-N

Selonabant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication. It was also previously being developed to treat obesity, but development for this indication was discontinued. The drug is administered by intravenous infusion. It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial. Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals. As of December 2024, it is in phase 2 trials.

See also